Safety and efficacy of the transition from subcutaneous treprostinil to oral Selexipag in patients with Pulmonary arterial hypertension

Trial Profile

Safety and efficacy of the transition from subcutaneous treprostinil to oral Selexipag in patients with Pulmonary arterial hypertension

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Jul 2017 New trial record
    • 24 May 2017 Preliminary results (n=3) presented at the 113th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top